Literature DB >> 20934262

Impact of salivary gland dosimetry on post-IMRT recovery of saliva output and xerostomia grade for head-and-neck cancer patients treated with or without contralateral submandibular gland sparing: a longitudinal study.

Zhong-He Wang1, Chao Yan, Zhi-Yuan Zhang, Chen-Ping Zhang, Hai-Sheng Hu, Wen-Yong Tu, Jessica Kirwan, William M Mendenhall.   

Abstract

PURPOSE: To observe the recovery of saliva output and effect on xerostomia grade after intensity-modulated radiotherapy (IMRT) with or without contralateral submandibular gland (cSMG) sparing and to assess the impact of salivary gland dosimetry on this recovery among patients with head-and-neck cancer. METHODS AND MATERIALS: Between May 2007 and May 2008, 52 patients with head-and-neck cancer received definitive (n=5 patients) and postoperative (n=47 patients) IMRT at our institution, with at least one parotid gland spared. Of these patients, 26 patients with a low risk of recurrence in the cSMG region underwent IMRT and had their cSMGs spared (cSMG-sparing group). The remaining 26 high-risk patients had no cSMGs spared (cSMG-unspared group). Xerostomia grades and salivary flow rates were monitored at five time points (before IMRT and at 2, 6, 12, and 18 months after IMRT).
RESULTS: Average mean doses and mean volumes receiving 30 Gy (V30) of the cSMGs were lower in the cSMG-sparing group than in the cSMG-unspared group (mean dose, 20.4 Gy vs. 57.4 Gy; mean V30, 14.7% vs. 99.8%, respectively). Xerostomia grades at 2 and 6 months post-IMRT were also significantly lower among patients in the cSMG-sparing group than in the cSMG-unspared group, but differences were not significant at 12 and 18 months after IMRT. Patients in the cSMG-sparing group had significantly better mean unstimulated salivary flow rates at each time point post- IMRT as well as better mean stimulated salivary flow rates at 2 months post-IMRT.
CONCLUSIONS: Recovery of saliva output and grade of xerostomia post-IMRT in patients whose cSMGs were spared were much better than in patients whose cSMGs were not spared. The influence of the mean doses to the cSMG and parotid gland on the recovery of saliva output was equivalent to that of the mean V30 to the glands.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20934262     DOI: 10.1016/j.ijrobp.2010.07.1990

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  21 in total

1.  Parotid gland-recovery after radiotherapy in the head and neck region--36 months follow-up of a prospective clinical study.

Authors:  Jeremias Hey; Juergen Setz; Reinhard Gerlach; Martin Janich; Guido Hildebrandt; Dirk Vordermark; Christian R Gernhardt; Thomas Kuhnt
Journal:  Radiat Oncol       Date:  2011-09-27       Impact factor: 3.481

2.  Reducing xerostomia after chemo-IMRT for head-and-neck cancer: beyond sparing the parotid glands.

Authors:  Michael Little; Matthew Schipper; Felix Y Feng; Karen Vineberg; Craig Cornwall; Carol-Anne Murdoch-Kinch; Avraham Eisbruch
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-11-04       Impact factor: 7.038

3.  Comparison of swallowing function after intensity-modulated radiation therapy and conventional radiotherapy for head and neck cancer.

Authors:  Barbara Roa Pauloski; Alfred W Rademaker; Jerilyn A Logemann; Muveddet Discekici-Harris; Bharat B Mittal
Journal:  Head Neck       Date:  2014-08-01       Impact factor: 3.147

4.  Sparing bilateral neck level IB in oropharyngeal carcinoma and xerostomia outcomes.

Authors:  Moses Tam; Nadeem Riaz; Danita Kannarunimit; Angela P Peña; Karen D Schupak; Daphna Y Gelblum; Suzanne L Wolden; Shyam Rao; Nancy Y Lee
Journal:  Am J Clin Oncol       Date:  2015-08       Impact factor: 2.339

Review 5.  Stem cell therapies for the treatment of radiation-induced normal tissue side effects.

Authors:  Marc Benderitter; Fabio Caviggioli; Alain Chapel; Robert P Coppes; Chandan Guha; Marco Klinger; Olivier Malard; Fiona Stewart; Radia Tamarat; Peter van Luijk; Charles L Limoli
Journal:  Antioxid Redox Signal       Date:  2014-02-03       Impact factor: 8.401

Review 6.  Cost-effectiveness landscape analysis of treatments addressing xerostomia in patients receiving head and neck radiation therapy.

Authors:  Laura S Sasportas; Drew N Hosford; Maria A Sodini; Dale J Waters; Elizabeth A Zambricki; Joëlle K Barral; Edward E Graves; Todd J Brinton; Paul G Yock; Quynh-Thu Le; Davud Sirjani
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol       Date:  2013-05-03

7.  Sparing the contralateral submandibular gland without compromising PTV coverage by using volumetric modulated arc therapy.

Authors:  Patricia Doornaert; Wilko F A R Verbakel; Derek H F Rietveld; Ben J Slotman; Suresh Senan
Journal:  Radiat Oncol       Date:  2011-06-16       Impact factor: 3.481

8.  Patterns of Relapse in Squamous Cell Carcinoma of the Tonsil - Unilateral vs. Bilateral Radiation in the HPV-Era.

Authors:  Allison Ye; Katherine L Bradley; Hosam Kader; John Wu; John H Hay
Journal:  Cureus       Date:  2015-09-10

9.  Submandibular gland-sparing radiation therapy for locally advanced oropharyngeal squamous cell carcinoma: patterns of failure and xerostomia outcomes.

Authors:  Michael F Gensheimer; Jay J Liao; Adam S Garden; George E Laramore; Upendra Parvathaneni
Journal:  Radiat Oncol       Date:  2014-11-26       Impact factor: 3.481

10.  Salivary gland-sparing other than parotid-sparing in definitive head-and-neck intensity-modulated radiotherapy does not seem to jeopardize local control.

Authors:  Enrique Chajon; Caroline Lafond; Guillaume Louvel; Joël Castelli; Danièle Williaume; Olivier Henry; Franck Jégoux; Elodie Vauléon; Jean-Pierre Manens; Elisabeth Le Prisé; Renaud de Crevoisier
Journal:  Radiat Oncol       Date:  2013-05-30       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.